How Bioscan Research is Changing the Game in Detecting Hidden Brain Injury
Some of the most serious injuries are the ones you cannot see. A person hits their head. They walk into a hospital. They talk, answer questions, and appear completely fine. Yet inside the skull, there may be bleeding that has not been detected. This silent danger makes timely diagnosis critical. Many wonder how is brain protected from injury and shock in such cases. Still, the reality is that natural protections like the skull and cerebrospinal fluid are not always enough against serious trauma.
In 2017, Shilpa Malik decided this was a problem worth solving. She co-founded Bioscan Research to address a critical gap in emergency care. The company’s flagship product, CEREBO, uses near-infrared light and artificial intelligence to detect intracranial bleeding quickly and non-invasively. This portable device works even when patients show no obvious symptoms, helping doctors make fast, life-saving decisions.
The innovation is particularly important because head injuries often have a narrow window for intervention. Detect the bleed early, and the patient has a significantly better chance of recovery. Miss it, and the damage can become permanent or fatal. CEREBO is designed to help medical teams act within that crucial window.
This week, Bioscan Research raised ₹9.65 crores in seed funding led by Unicorn India Ventures. The capital will support market expansion, additional regulatory approvals, and further upgrades to the device. For a deep-tech startup tackling one of medicine’s most challenging areas, this funding marks an important validation.
Why Early Detection of Brain Bleeds Matters
Understanding how is brain protected from injury and shock helps explain why tools like CEREBO are revolutionary. The brain is shielded by the skull, meninges, and cerebrospinal fluid, which act as natural shock absorbers. However, high-impact trauma can still cause blood vessels to rupture, leading to intracranial hemorrhage. Traditional diagnosis relies on CT scans, which may not be immediately available in smaller hospitals or during emergencies.
CEREBO changes this equation. Using near-infrared spectroscopy, it penetrates the skull to detect bleeding in real time. The AI component analyses the data and provides clear results to clinicians. This combination of advanced optics and machine learning makes it possible to identify problems that would otherwise remain hidden until symptoms worsen.
The device is especially valuable in India’s diverse healthcare landscape. In rural and semi-urban areas, access to CT scanners is limited. CEREBO’s portable, affordable design brings advanced diagnostics closer to where they are needed most — emergency rooms across the country.
A Founder’s Determination in Deep Tech
Shilpa Malik’s journey into deep technology and medical devices is inspiring. Building a product that deals with brain injuries requires not only technical expertise but also a deep sense of purpose. Every decision impacts lives measured in minutes. The startup’s focus on creating an Indian solution for Indian healthcare challenges reflects a commitment to accessibility and impact.
The recent funding round will help Bioscan Research expand into new markets, strengthen manufacturing capabilities, and accelerate clinical validation. As more hospitals adopt CEREBO, the potential to save lives and reduce long-term disability from head injuries grows significantly.
The Science Behind the Innovation
To appreciate CEREBO fully, it helps to revisit how is brain protected from injury and shock naturally. The skull provides a rigid outer layer, while cerebrospinal fluid cushions the brain against sudden movements. However, in cases of trauma, these protections can be overwhelmed, leading to bleeding or swelling inside the confined space of the skull. This increases intracranial pressure and can cause irreversible damage if not addressed quickly.
CEREBO’s technology detects changes in light absorption caused by blood accumulation. The device is non-invasive, requires minimal training, and delivers results rapidly. This makes it suitable for use in ambulances, small clinics, and busy emergency departments alike.
Broader Impact on Emergency Medicine
The implications extend far beyond individual cases. Faster detection of brain bleeds can reduce mortality rates, shorten hospital stays, and lower overall healthcare costs. For athletes, road accident victims, and elderly patients prone to falls, such technology could become standard care.
Bioscan Research’s work also highlights the growing role of Indian deep-tech startups in solving critical healthcare problems. By building affordable, locally relevant solutions, companies like this are strengthening the country’s medical technology ecosystem.
Looking Ahead
With the new funding, Bioscan Research is poised for the next phase of growth. Plans include wider regulatory clearances, international market entry, and continuous improvement of the AI algorithms. The ultimate goal is to make rapid, accurate brain bleed detection available in every emergency setting where it is needed.
Shilpa Malik and her team are proving that deep technology developed in India can compete globally while addressing local challenges first. Their work reminds us that healthcare innovation often comes from identifying gaps in critical care and having the courage to solve them.
As awareness grows about how is brain protected from injury and shock — and where those protections can fail — tools like CEREBO will become increasingly important. In emergency medicine, every minute counts. Bioscan Research is working to ensure those minutes are used effectively to save lives and preserve brain function.
The journey from idea to impactful product is never easy, especially in regulated fields like medical devices. Yet stories like this show what is possible when technical excellence meets a clear sense of purpose.
India’s healthcare innovation story is still being written. With startups like Bioscan Research pushing boundaries in diagnostics and emergency care, the future looks brighter — and safer — for patients across the country.